Response assessment classifications of 50 MR imaging time points for 3 tumor-management strategiesa
Clinical CP | Semiautomated CP | Volume (25/50) | Volume (40/65) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
PR | SD | PD | PR | SD | PD | PR | SD | PD | PR | SD | PD | |
Clinical CP | ||||||||||||
PR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
SD | 2 | 25 | 14 | 2 | 23 | 16 | 1 | 32 | 8 | |||
PD | 0 | 2 | 7 | 0 | 2 | 7 | 0 | 3 | 6 | |||
Concordance | 64% | 60% | 76% | |||||||||
Semiautomated CP | ||||||||||||
PR | 2 | 0 | 0 | 1 | 1 | 0 | ||||||
SD | 0 | 20 | 7 | 0 | 25 | 2 | ||||||
PD | 0 | 5 | 16 | 0 | 9 | 12 | ||||||
Concordance | 76% | 76% | ||||||||||
Volume | ||||||||||||
PR | 1 | 1 | 0 | |||||||||
SD | 0 | 25 | 0 | |||||||||
PD | 0 | 9 | 14 | |||||||||
Concordance | 80% |
↵a Two different tumor-response criteria were applied to the volume data (25/50 uses the same criteria as used for CP-response determinations, 40/65 denotes PR as >65% decrease from baseline and PD as >40% increase from the prior lowest tumor size). Unless otherwise noted, values represent the number of MR imaging time points.